
Denali Therapeutics Inc.: stock overview
Price
$18.45
November 20, 2026Market cap $2.9B
What Ploutos Investor adds for Denali Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Denali Therapeutics had revenue of $21M over the last 12 months and a net loss of $314M. It holds more cash than debt, by $511M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $2.9B
- 159M shares
- P/E
- –
- Revenue, 12 months
- $21M
- Net margin
- -1,470.5%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Fiscal years in figures
DNLI's revenue, profit, cash flow and dividend with each year-end price, from 2016 to 2022, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $3.0B
- $2.9B
- Enterprise value
- $2.4B
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 113.0
- P/B 3-year median: 2.6
- 3.2
- FCF yield 3-year median: -12.4%
- –
- Earnings yield 3-year median: -12.6%
- –
Profitability
- Operating margin
- -2,488.1%
- Net margin
- -1,470.5%
- ROIC
- -45.4%
- ROIC, 5-year average
- -28.0%
- ROE
- -34.0%
Growth
Sorry, we do not have enough data
for the “Growth” group
Balance sheet
- Cash
- $516M
- Total debt
- $35M
- Of which operating leases
- $30M
- Net cash
- $511M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 6.21
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +9.2%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Denali Therapeutics Inc.
- CIK
- 1714899
- Exchange
- NASDAQ
- Industry (SIC)
- 2836 · Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 159M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with DNLI
- JNJJohnson & Johnson+0,00%Compare with DNLI
- ABBVAbbVie+0,00%Compare with DNLI
- UNHUnitedHealth+0,00%Compare with DNLI
- MRKMerck & Company+0,00%Compare with DNLI
- AMGNAmgen+0,00%Compare with DNLI
- TMOThermo Fisher Scientific+0,00%Compare with DNLI
- ABTAbbott Laboratories+0,00%Compare with DNLI
The full analysis
What do Denali Therapeutics's filings show?
These are Denali Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is DNLI's market cap?
Denali Therapeutics Inc.'s market cap is $2.9B, at a price of $18.45 on November 20, 2026 and 159M shares.
How much revenue does DNLI have?
Denali Therapeutics had revenue of $21M over the last 12 months.
Does DNLI pay a dividend?
No. Denali Therapeutics paid no regular dividend over the last 12 months.
Where do the figures come from?
From Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.